Africa: Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low – and Middle-Income Countries
Geneva — A pivotal moment in the fight to end AIDS — ensuring lifesaving innovation reaches those who need it most, wherever they live The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced it has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV…